Viking Therapeutics shares surge on obesity drug data as Novo falls
Lilly shares also rose on the readout, while Novo Nordisk declined, according to Investor's Business Daily.
TR
By Tom Reyes · Markets Editor
Sep 22 03:00 ETSource: Investor's Business Daily
The wire
- 01Investor's Business Daily reports Viking Therapeutics stock jumped on new obesity drug data, with Eli Lilly shares rising and Novo Nordisk shares falling the same session.
- 02Incretin competition shapes supply, pricing and compounding demand that telehealth operators and pharmacies track closely.
- 03The report does not detail the endpoints, dosing or safety data behind the move; full trial results will determine how the asset stacks up against approved incretins.
From the source
Read at investors.comViking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.
